Combination of Mcl-1 (Myeloid-Cell Leukemia 1) and Bcl-2 (B-Cell Lymphoma 2) inhibition – A novel treatment approach for Hepatocellular Carcinoma (HCC)

Introduction Hepatocellular Carcinoma is one of the most common malignancies worldwide and has the third-highest mortality rate of all cancerous diseases. Late diagnosis and resistance towards medication often prevent successful therapy. Therefore, new systemic treatment alternatives are needed. The use of BH3-mimetics constitutes a novel approach. These inhibitors bind pro-survival-proteins of the Bcl-2-family resulting in induction of apoptosis.